Contribution of fetal tricuspid regurgitation in first-trimester screening for major cardiac defects

Obstetrics and Gynecology

Volumn 117, Issue 6, 2011, Pages 1384-1391

  Pereira, Susana ^a,b,c,d   Ganapathy, Ramesh ^a,b,c,d   Syngelaki, Argyro ^a,b,c,d   Maiz, Nerea ^a,b,c,d   Nicolaides, Kypros H ^a,b,c,d  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b MEDWAY MARITIME HOSPITAL   (United Kingdom)

^c Centro Sanitario Virgen Del Pilar   (Spain)

^d UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MARKER;

A WAVE; ADOLESCENT; ADULT; ANEUPLOIDY; AORTA COARCTATION; AORTA STENOSIS; ARTICLE; BLOOD FLOW; CONFIDENCE INTERVAL; DUCTUS VENOSUS; EBSTEIN ANOMALY; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATION PERIOD; HEART ATRIUM SEPTUM DEFECT; HEART DISEASE; HEART VENTRICLE SEPTUM DEFECT; HUMAN; NEWBORN SCREENING; NUCHAL TRANSLUCENCY MEASUREMENT; PERFORMANCE; PRIORITY JOURNAL; PULMONARY VALVE ATRESIA; PULMONARY VALVE STENOSIS; TRICUSPID VALVE; TRICUSPID VALVE ATRESIA; TRICUSPID VALVE REGURGITATION;

ADOLESCENT; ADULT; FEMALE; FETAL DISEASES; HEART DEFECTS, CONGENITAL; HUMANS; MIDDLE AGED; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY TRIMESTER, FIRST; TRICUSPID VALVE INSUFFICIENCY; YOUNG ADULT;

EID: 79955025795     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e31821aa720     Document Type: Article

References (31)

1. Allan LD, Sharland GK, Milburn A, Lockhart SM, Groves AM, Anderson RH, et al. Prospective diagnosis of 1,006 consecutive cases of congenital heart disease in the fetus. J Am Coll Cardiol 1994;23:1452-8. (Pubitemid 24158017)
2. Bull C. Current and potential impact of fetal diagnosis on prevalence and spectrum of serious congenital heart disease at term in the UK. British Paediatric Cardiac Association. Lancet 1999;354:1242-7, ik. (Pubitemid 29469352)
3. Bricker L, Garcia J, Henderson J, Mugford M, Neilson J, Roberts T, et al. Ultrasound screening in pregnancy: a systematic review of the clinical effectiveness, cost-effectiveness and women's views. Health Technol Assess 2000;4:i-vi, 1-193.
4. Tegnander E, Williams W, Johansen OJ, Blaas HG, Eik-Nes SH. Prenatal detection of heart defects in a non-selected population of 30,149 fetuses- detection rates and outcome. Ultrasound Obstet Gynecol 2006;27:252-65. (Pubitemid 43735497)
5. Allan LD. Echocardiographic detection of congenital heart disease in the fetus: present and future. Br Heart J 1995;74: 103-6.
6. Hyett J, Perdu M, Sharland G, Snijders R, Nicolaides KH. Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: population based cohort study. BMJ 1999;318:81-5. (Pubitemid 29188923)
7. Atzei A, Gajewska K, Huggon IC, Allan L, Nicolaides KH. Relationship between nuchal translucency thickness and prevalence of major cardiac defects in fetuses with normal karyotype. Ultrasound Obstet Gynecol 2005;26:154-7. (Pubitemid 41540299)
8. Matias A, Huggon I, Areias JC, Montenegro N, Nicolaides KH. Cardiac defects in chromosomally normal fetuses with abnormal ductus venosus blood flow at 10-14 weeks. Ultrasound Obstet Gynecol 1999;14:307-10. (Pubitemid 30032352)
9. Maiz N, Valencia C, Emmanuel EE, Staboulidou I, Nicolaides KH. Screening for adverse pregnancy outcome by ductus venosus Doppler at 11-13 6 weeks of gestation. Obstet Gynecol 2008;112:598-605.
10. Maiz N, Plasencia W, Dagklis T, Faros E, Nicolaides K. Ductus venosus Doppler in fetuses with cardiac defects and increased nuchal translucency thickness. Ultrasound Obstet Gynecol 2008;31:256-60.
11. Syngelaki A, Chelemen T, Dagklis T, Allan L, Nicolaides KH. Challenges in the diagnosis of fetal non-chromosomal abnormalities at 11-13 weeks. Prenat Diagn 2011;31:90-102.
12. Chelemen T, Syngelaki A, Maiz N, Allan L, Nicolaides KH. Contribution of ductus venosus Doppler in first trimester screening for major cardiac defects. Fetal Diagn Ther 2011;29: 127-34.
13. Huggon IC, DeFigueiredo DB, Allan LD. Tricuspid regurgitation in the diagnosis of chromosomal anomalies in the fetus at 11-14 weeks of gestation. Heart 2003;89:1071-3. (Pubitemid 37046850)
14. Faiola S, Tsoi E, Huggon IC, Allan LD, Nicolaides KH. Likelihood ratio for trisomy 21 in fetuses with tricuspid regurgitation at the 11 to 13 6-week scan. Ultrasound Obstet Gynecol 2005;26:22-7. (Pubitemid 41537007)
15. Falcon O, Faiola S, Huggon I, Allan L, Nicolaides KH. Fetal tricuspid regurgitation at the 11 to 13week scan: association with chromosomal defects and reproducibility of the method. Ultrasound Obstet Gynecol 2006;27:609-12. (Pubitemid 43967360)
16. Kagan KO, Valencia C, Livanos P, Wright D, Nicolaides KH. Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 1113 weeks of gestation. Ultrasound Obstet Gynecol 2009;33:18-22.
17. Robinson HP, Fleming JE. A critical evaluation of sonar 'crown-rump length' measurements. Br J Obstet Gynaecol 1975;82:702-10.
18. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998;352:343-6. (Pubitemid 28352196)
19. Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 2008;31:618-24.
20. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-77. (Pubitemid 23118304)
21. Ferencz C, Rubin JD, McCarter RJ, Brenner JI, Neill CA, Perry LW. Congenital heart disease: prevalence at livebirth. The Baltimore-Washington infant study. Am J Epidemiol 1985;121:31-6. (Pubitemid 15150685)
22. Nicolaides KH, Azar G, Byrne D, Mansur C, Marks K. Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. BMJ 1992;304:867-9.
23. Brizot ML, Snijders RJ, Bersinger NA, Kuhn P, Nicolaides KH. Maternal serum pregnancy associated placental protein A and fetal nuchal translucency thickness for the prediction of fetal trisomies in early pregnancy. Obstet Gynecol 1994;84:918-22. (Pubitemid 24360247)
24. Noble PL, Abraha HD, Snijders RJ, Sherwood R, Nicolaides KH. Screening for fetal trisomy 21 in the first trimester of pregnancy: maternal serum free beta-hCG and fetal nuchal translucency thickness. Ultrasound Obstet Gynecol 1995;6: 390-5.
25. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 1999;13:231-7. (Pubitemid 29248329)
26. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM; SURUSS Research Group. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technol Assess 2003;7:1-77.
27. Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, et al; First-and Second-Trimester Evaluation of Risk (FASTER) Research Consortium. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005;353:2001-11.
28. Nicolaides KH. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn 2011;31:7-15.
29. Screening for fetal chromosomal abnormalities. ACOG Practice Bulletin No. 77. American College of Obstetricians and Gynecologists. Obstet Gynecol 2007;109:217-28.
30. National Institute for Health and Clinical Excellence. NICE Clinical Guideline 62. Antenatal care: routine care for the healthy pregnant woman. London: National Institute for Health and Clinical Excellence; 2008.
31. Maiz N, Valencia C, Kagan KO, Wright D, Nicolaides KH. Ductus venosus Doppler in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation. Ultrasound Obstet Gynecol 2009;33:512-7.